Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

NCT06719700 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Toripalimab
Surufatinib
Chemoradiotherapy
Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventions

DRUG: Chemotherapy
DRUG: Immunotherapy
DRUG: Angio-immuno kinase inhibitor
RADIATION: radiotherapy
RADIATION: Prophylactic Cranial Irradiation
DRUG: Consolidation Therapy with Toripalimab and Surufatinib

Sponsor

Sun Yat-sen University